Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of YD0293 in Healthy Subjects

Phase 1 Enrolling by invitation 78 enrolled Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a single-center, single- and multiple-dose escalating study with a food-effect component, designed to evaluate the safety, tolerability, and pharmacokinetic (PK) characteristics of YD0293 tablets following a single oral dose in healthy subjects, as well as the effect of food on PK parameters and the potential effect on the QT interval. The study also aims to assess the safety, tolerability, and PK profile of YD0293 tablets following multiple oral doses in healthy subjects.

Timeline

Start: 2025-02-26
Primary completion: 2025-12-31
Completion: 2025-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	YD0293	Unknown	—	Oral

Indications

No indication recorded.